1. Stephen Clulow, Jane Osbourn, John Elvin Presented by Stephen Clulow Director of Knowledge and Information Management and Informatics R&D Operations and Strategy A Simple Open Innovation Approach Helps Solve Real Business Challenges
4. Collaborative Process 8 Challenges 8 MedI Mentors Non-confidential background information PDR approved Post-docs, PhD students, Undergrads Recruited by CUTEC All university departments 1 team per challenge Ideation and Incubation Meet mentor 1.5 hr brainstorm Build ideas for 1 week in team, with mentor Present Ideas Novelty Feasibility Quality Assessed by 4 VPs
5. Generates New, Useful Ideas “ Enjoyable”, “Interesting”, “A blast” Addressed real challenges that we face Generated ideas new to, and useful to, MedImmune ≥ 10 ideas worth developing further in MedImmune Improved MedImmune’s external profile Everyone wants to repeat the event next year
8. Taking MedI Innovation to the Next Level First venture into open innovation Successful outcome Desire to use format internally … and externally
Editor's Notes
AstraZeneca has consolidated all its biologics workflows, including its investments in Cambridge Antibodies Therapeutics and Abgenix under the MedImmune banner. Our meteoric innovation continues as we put the finishing touches on our new biologics manufacturing facility near our global headquarters in Maryland – it’s a strategic investment by any measure that was more than half-way finished prior to AZ’s acquisition. It will be an innovative asset for the entire AZ global, biologics portfolio going forward. It’s an accurate picture to describe each of these outlined points as a cylinder in a high-performance engine – our new, high-efficiency front-wheel drive MedImmune engine has all-wheel drive capability and is currently being added to the rear-wheel drive AZ engine. Both engines operate separately – but both keep the AstraZeneca vehicle moving forward. Our commitment to innovation and intelligent risk are the high-test fuel and high-performance upgrades that AZ wanted and needed to make to its ride. For all of these reasons the inertia of innovation will not stop at MedImmune…..
![MedImmune ,[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)